Mr. Sherman has served as General Counsel for private and public development stage pharmaceutical and biotechnology companies for over 40 years, including most recently Marinus Pharmaceuticals, Inc., TetraLogic Pharmaceuticals Corporation, Actinium Pharmaceuticals, Inc. and Hawaii Biotech, Inc.. He is also a principal in a private SBIC Investment fund, CIP Capital, L.P., a venture partner in the SCP/Vitalife family of funds in suburban Philadelphia, and a consultant to the law firm of Goodsill Anderson Quinn & Stifel, in Honolulu, Hawaii. He spent more than a decade (1976-1989) as Deputy General Counsel of SmithKline Beckman Corporation (now GlaxoSmithKline), was a partner in the law firm of Pepper Hamilton LLP (1990-1992), and was founder and managing officer (1992-2001) of QED Technologies, Inc., a life science business consulting firm purchased in 1999 by The Omnicom Group in New York.
Mr. Sherman has served on the Board of Directors of a number of public and private for-profit companies in the United States and Canada, including Biophage, Inc., CytoMed, Inc., Functional Technologies Corp., IBAH, Inc., Kenna Technologies, Inc., Leversense LLC, Mera Pharmaceuticals, Inc., Sparta Pharmaceuticals and Immunomedics, Inc. He is currently a member of the Board of Directors of Hawaii Biotech, Inc. and PONTiS Orthopedics LLC.
His non-profit and charitable activities have included service on the Boards of the Pennsylvania Biotechnology Association, the Delaware Valley Chapter of the American Corporate Counsel Association (where he also served as President of the chapter), the American Music Theater Festival (also serving as President), Aloha Medical Mission, The Sbarro Health Research Organization, the Hawaii Venture Capital Association, The St. Andrew Society (Hawaii), the Caledonian Society (Hawaii), and the Hawaii Science and Technology Council. He has also served as a member of the investment advisory committee of the Ben Franklin Technology Center, the Executive Board of the START Technology Partnership, a consortium of Delaware Valley universities, The Technology Advisory Board for Children’s Hospital of Philadelphia, and the Advisory Board of the University of Hawaii Medical School.
Mr. Sherman graduated magna cum laude from the University of Nebraska (1968), where he was elected to Phi Beta Kappa. As a Root-Tilden Scholar at the New York University School of Law, he received his Juris Doctor in 1971.
Therapy Architects designs and develops novel targeted cancer therapies for both children and adults. Every patient is unique and not all respond to available products. Our team is focused on improving outcomes by optimizing efficacy and reducing toxic side effects of chemotherapeutic agents where, the cure can sometimes be worse than the disease itself.
© 2016 Therapy Architects. All rights reserved